Health & Medical Diabetes

Dipeptidyl Peptidase-4 Inhibitors and Bone Fractures

Dipeptidyl Peptidase-4 Inhibitors and Bone Fractures

Abstract and Introduction

Abstract


Objective—Thiazolidinediones and insulin are associated with a higher risk of fractures in type 2 diabetic patients. Incretin hormones increase bone density in experimental models, but the effect of dipeptidyl peptidase-4 (DPP-4) inhibitors on bone fractures has not been reported so far.
Research Design and Methods—A meta-analysis was performed including all randomized clinical trials with a duration of at least 24 weeks, enrolling patients with type 2 diabetes, comparing DPP-4 inhibitors with placebo or active drugs.
Results—Twenty-eight trials enrolling 11,880 and 9,175 patients for DPP-4 inhibitors and comparators, respectively, were included, reporting 63 fractures. DPP-4 inhibitors, compared with placebo or other treatments, were associated with a reduced risk of fractures (Mantel–Haenszel odds ratio [MH-OR] 0.60, 95% CI 0.37–0.99, P = 0.045), even after the exclusion of comparisons with thiazolidinediones or sulfonylureas (MH-OR 0.56, 0.33–0.93, P = 0.026).
Conclusions—The present meta-analysis suggests that treatment with DPP-4 inhibitors could be associated with a reduced risk of bone fractures.

Introduction


Type 2 diabetes is associated with an increased risk for bone fractures. The higher risk could be determined by several factors, including falls, diabetes complications, and comorbidities. Moreover, glucose-lowering agents such as thiazolidinediones have been reported to reduce bone density and to increase the incidence of fractures in longer-term trials and in epidemiologic studies. Insulin therapy is also associated with an increased fracture risk despite its neutral effect on bone density. The increased risk of falls, due to hypoglycemia, could lead to higher fracture risk.

Glucagon-like peptide-1 (GLP-1) has been reported to induce osteoblast differentiation and inhibit osteoclastic activity; GLP-1 receptor agonists stimulate bone formation in rodents. Experimental data in animal models suggest that gastric intestinal polypeptide is also capable of increasing bone density. Drugs capable of increasing incretin levels, such as dipeptidyl peptidase-4 (DPP-4) inhibitors, could therefore exert beneficial effects on the bone.

SHARE
RELATED POSTS on "Health & Medical"
New Information on Type 2 Diabetes
New Information on Type 2 Diabetes
Type 2 Diabetes - Preventing Gestational Diabetes
Type 2 Diabetes - Preventing Gestational Diabetes
Diabetes 2 Treatment- A Time to Act
Diabetes 2 Treatment- A Time to Act
FDA Approves New Diabetes Drug Symlin
FDA Approves New Diabetes Drug Symlin
About Insulin
About Insulin
Gestational Diabetes Diet Plan
Gestational Diabetes Diet Plan
How To Treat Focal Segmental Glomerulosclerosis (fsgs) Effectively
How To Treat Focal Segmental Glomerulosclerosis (fsgs) Effectively
Study Explains Why Diabetics Face High Risk From Angioplasty
Study Explains Why Diabetics Face High Risk From Angioplasty
Diabetic Testing Supplies
Diabetic Testing Supplies
Diabetes - 5 Ways to Save Money on Medicine
Diabetes - 5 Ways to Save Money on Medicine
Diabetes and Exercise
Diabetes and Exercise
Use of U-500 Insulin in Continuous Subcutaneous Insulin Infusion
Use of U-500 Insulin in Continuous Subcutaneous Insulin Infusion
Alternative Health - 7 Tips to Help With Your Weight Loss and Type 2 Diabetes
Alternative Health - 7 Tips to Help With Your Weight Loss and Type 2 Diabetes
A Guide to Symptoms of Diabetes
A Guide to Symptoms of Diabetes
Type 2 Diabetes Treatment Victoza Helps Type 1, Too
Type 2 Diabetes Treatment Victoza Helps Type 1, Too
Blood Sugar Level
Blood Sugar Level
What is Monavie?
What is Monavie?
Diabetic Muscle Infarction: A Systematic Review
Diabetic Muscle Infarction: A Systematic Review
How Is an Epidemiological Study Carried Out?
How Is an Epidemiological Study Carried Out?
We Can Change the Natural History of Type 2 Diabetes
We Can Change the Natural History of Type 2 Diabetes

Leave Your Reply

*